Gunning for new targets, new approaches
Gunning for new targets, new modalities, and fresh directions
As we look at various emerging early stage oncology pipelines and think about future rising stars, there are a few which stand out for their sheer depth and breadth.
There are some intriguing similarities between them in they have forged multiple collaborations with selective young biotechs over the last few years rather than rely solely on in-house production.
In our latest review, we look at one of these companies and discuss how the various pillars they have chosen to focus on not only fit together, but also lend themselves to cross modality fusion.
The end result is a vibrant pipeline capable of fueling their life cycle management portfolio for quite a few years to come…
To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
